Skip to main content
. 2022 Feb 9;3(1):e118. doi: 10.1002/mco2.118

TABLE 1.

G‐ and GO‐based nanosystems for cancer therapy with promising advantages

G‐ and GO‐based nanosystems Applications Important features Refs.
Multifunctionalized GO Targeted cancer therapy and drug delivery

– No noticeable toxic effects

– Higher drug stacking capability

– pH‐responsive drug discharge features

– Particular target transport and effectual cell inhibition

100
Carboxymethyl cellulose‐GO Targeted and sustained drug delivery

– No noticeable toxicity with sustained and prolonged release of doxorubicin

– Incorporation of GO nanosheets highly improved the swelling capacity of hydrogels

118
GO Cancer therapy and drug delivery system

– Sustained‐release nanoformulation

– Improved suppression of cancer cell growth

119
GO‐hyaluronic acid‐Arg‐Gly‐Asp peptide Targeted cancer therapy and anticancer drug delivery

– Low toxicity

– High drug loading

– Improved specificity and efficiency of anticancer drug delivery

120
Magnetic GO‐chitosan‐PEG‐N‐Hydroxysuccinimide Anticancer drug delivery system

– Good biocompatibility

– Low cytotoxicity

– pH‐responsive controllable drug release behavior

– High drug loading potentials

121
polyvinylpyrrolidone‐ and β‐cyclodextrin‐modified GO Targeted anticancer drug delivery

– Low toxicity

– pH‐dependent drug release

122
GO@soy phosphatidylcholine‐folic acid nanohybrid Antitumor therapy and targeted drug delivery

– No noticeable toxicity

– pH‐dependable drug release

– Improved steadiness and good biocompatibility

– Higher drug packing ability

– Effectual cellular uptake

– Regulated drug discharge

123
Chitosan‐grafted‐poly(methacrylic acid)/GO Anticancer drug delivery

– No detectable toxicity

– Significant biocompatibility

– High drug packing capacity

– pH‐dependent drug delivery performance

124
GO/chitosan oligosaccharide/γ‐polyglutamic acid Anticancer drug delivery

– No detectable toxicity

– Simple delivery and controllable anticancer drug release behavior

125
Superparamagnetic iron oxide‐GO Smart nanotheranostics platform

– Good biocompatibility

– pH‐dependable drug release

126
Chitosan‐carboxylated GO Gene delivery – High gene transferring properties 127
Modified GO Gene delivery

– Low toxicity

– Improved release of DNA

– Suitable interaction with DNA and hydrophobic immune adjuvant

128
GO/ethylene glycol‐polycaprolactone Anticancer drug delivery; tumor therapy

– Low cytotoxicity

– Improved biocompatibility and biodegradability

– High drug release and inhibition of tumor growth

129
GO‐nanoscale hydroxyapatite Cancer therapy (chemotherapy and photothermal therapy)

– High biocompatibility

– High photothermal therapy activity

– Improved drug release behavior

– High drug loading capacity

130
Polymer G nano‐aerogels Anticancer drug delivery – High anticancer drug‐releasing with pH‐dependable behavior 131
Starch‐G nanosheets Anticancer drug delivery

– High anticancer drug loading capacity

– Sustained‐release behavior

– Good biocompatibility

– Low toxicity with improved therapeutic efficacy

132
Reduced‐GO nanostructures Cancer therapy and anti‐inflammatory effects – Anti‐proliferative activity with high efficacy 133
Reduced‐GO nanostructures Anticancer drug delivery

– Sustained pH‐sensitive drug release

– Improved therapeutic efficacy

– High drug loading capacity

– High hemolytic toxicity to rabbit red blood cells

101
Nanoscale GO loaded with HN‐1 (a tumor‐targeted peptide) Anticancer drug delivery

– High stability to the biological solution

– High tumor‐targeting behavior

– pH‐responsive drug release

– High cellular uptakes and cytotoxicity toward tumor cells

134
D‐mannose‐mediated chitosan‐functionalized GO nanosystems Anticancer drug delivery

– Good biocompatibility

– Targeted and controlled delivery

– Intracellular discharge of marine algae‐mediated anticancer drugs versus glioblastoma cancers (e.g., ulvan)

135
5‐Fluorouracil and curcumin loaded chitosan/reduced GO nanocomposites Anticancer drug delivery

– Synergistic inhibitory effects against the growth of HT‐29 colon cancerous cells

– Dual‐drug loading properties

– Improved targeting properties

136